Export 2409 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Chapple, C. R., Cruz, F., Deffieux, X., Milani, A. L., et al. (2017). Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. European Urology, 72(3), 424 - 431.
Charrua, A., Avelino, A., & Cruz, F. (2011). Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. Handbook of Experimental Pharmacology (Vol. 202, pp. 345 - 374).
Charrua, A., Cruz, C. D., Narayanan, S., Gharat, L., et al. (2009). GRC-6211, a New Oral Specific TRPV1 Antagonist, Decreases Bladder Overactivity and Noxious Bladder Input in Cystitis Animal Models. Journal of Urology, 181(1), 379 - 386.
Charrua, A., Cruz, C. D., Cruz, F., & Avelino, A. (2007). Transient Receptor Potential Vanilloid Subfamily 1 is Essential for the Generation of Noxious Bladder Input and Bladder Overactivity in Cystitis. Journal of Urology, 177(4), 1537 - 1541.
Charrua, A., & Cruz, F. (2015). Intravesical Capsaicin and Resiniferatoxin for Bladder Disorders. In TRP Channels as Therapeutic Targets: From Basic Science to Clinical Use (pp. 119 - 127).
Charrua, A., Cruz, C. D., Jansen, D., Rozenberg, B., et al. (2015). Co-administration of transient receptor potential vanilloid 4 (TRPV4) and TRPV1 antagonists potentiate the effect of each drug in a rat model of cystitis. BJU International, 115(3), 452 - 460.
Charrua, A., Reguenga, C., Paule, C. C., Nagy, I., et al. (2008). Cystitis is associated with TRPVIb-downregulation in rat dorsal root ganglia. NeuroReport, 19(15), 1469 - 1472.
Charrua, A., Reguenga, C., Cordeiro, J. M., Correiade-Sá, P., et al. (2009). Functional Transient Receptor Potential Vanilloid 1 is Expressed in Human Urothelial Cells. Journal of Urology, 182(6), 2944 - 2950.
Charrua, A., Pinto, R., Taylor, A., Canelas, A., et al. (2015). Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourology and Urodynamics, 34(5), 489 - 496.
Chavarria, D., Silva, T., Martins, D., Bravo, J., et al. (2015). Exploring cinnamic acid scaffold: development of promising neuroprotective lipophilic antioxidants. MedChemComm, 6(6), 1043 - 1053.
Chaves, J., Beirão, I., Balreira, A., Gaspar, P., et al. (2011). Progressive myoclonus epilepsy with nephropathy C1q due to SCARB2/LIMP-2 deficiency: Clinical report of two siblings. Seizure, 20(9), 738 - 740.
Chen, Z., Wang, C., Zheng, C., Long, Z., et al. (2017). Ubiquitin-related network underlain by (CAG)nloci modulate age at onset in Machado-Joseph disease. Brain, 140(4), e25.
Chen, Z., Zheng, C., Long, Z., Cao, L., et al. (2016). (CAG)nloci as genetic modifiers of age-at-onset in patients with Machado-Joseph disease from mainland China. Brain, 139(8), e41.
Cherif, W., Ben Turkia, H., Ben Rhouma, F., Riahi, I., et al. (2009). Gaucher disease in Tunisia: High frequency of the most common mutations. Blood Cells, Molecules, and Diseases, 43(2), 161 - 162.
Cho, K., Jang, J. H., Kim, S. - P., Lee, S. H., et al. (2016). Analysis of nociceptive information encoded in the temporal discharge patterns of cutaneous C-fibers. Frontiers in Computational Neuroscience, 10(NOV).
Cimino, M., Gonçalves, R. M., Bauman, E., Barroso-Vilares, M., et al. (2018). Optimization of the use of a pharmaceutical grade xeno-free medium for in vitro expansion of human mesenchymal stem/stromal cells. Journal of Tissue Engineering and Regenerative Medicine, 12(3), e1785 - e1795.
Clayton, G. M., Aller, S. G., Wang, J., Unger, V., & Morais-Cabral, J. H. (2009). Combining electron crystallography and X-ray crystallography to study the MlotiK1 cyclic nucleotide-regulated potassium channel. Journal of Structural Biology, 167(3), 220 - 226.
Clayton, G. M., Altieri, S., Heginbotham, L., Unger, V. M., & Morais-Cabral, J. H. (2008). Structure of the transmembrane regions of a bacterial cyclic nucleotide-regulated channel. Proceedings of the National Academy of Sciences of the United States of America, 105(5), 1511 - 1515.
Coelho, A., Cruz, F., Cruz, C. D., & Avelino, A. (2012). Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. European Urology, 61(6), 1178 - 1184.
Coelho, S. C., Rocha, S., Sampaio, P., Pereira, M. C., & Coelho, M. A. N. (2014). Encapsulation of a proteasome inhibitor with gold-polysaccharide nanocarriers. Journal of Nanoparticle Research, 16(4).
Coelho, J., Nandyala, S. H., Gomes, P. S., Sampaio, P., et al. (2012). Development and characterization of Ag 2 O-doped ZnLB glasses and biological assessment of Ag 2 O - ZnLB-hydroxyapatite composites. Journal of the American Ceramic Society, 95(9), 2732 - 2740.
Coelho, A., Wolf-Johnston, A. S., Shinde, S., Cruz, C. D., et al. (2015). Urinary bladder inflammation induces changes in urothelial nerve growth factor and TRPV1 channels. British Journal of Pharmacology, 172(7), 1691 - 1699.
Coelho, S. C., Rocha, S., Juzenas, P., Sampaio, P., et al. (2013). Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells. Expert Opinion on Drug Delivery, 10(10), 1345 - 1352.
Coelho, A., Dinis, P., Pinto, R., Gorgal, T., et al. (2010). Distribution of the High-Affinity Binding Site and Intracellular Target of Botulinum Toxin Type A in the Human Bladder. European Urology, 57(5), 884 - 890.
Coelho, A., Cruz, F., Cruz, C. D., & Avelino, A. (2012). Reply from Authors re: Prokar Dasgupta. Volume matters: Bladder injections of botulinum toxin type A. Eur Urol 2012;61:1185-6: Yes, Volume matters: Bladder injections of botulinum toxin type A. European Urology, 61(6), 1186 - 1187.

Pages


Home | Site Map | Contacts | Credits | Privacy & Cookies | WHISTLEBLOWER CHANNEL | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 226 074 900 | email: info@i3s.up.pt | © copyright 2010 ibmc